OSLO, Norway, March 11, 2020 /PRNewswire/ -- Targovax ASA
(OSE: TRVX), a clinical stage biotechnology company developing
immune activators to target hard-to-treat solid tumors, today
announces its fourth quarter 2019 results.
A meeting for investors, analysts and press will take place
in Oslo today at 10:00 CET (details below).
HIGHLIGHTS FOR THE FOURTH QUARTER
2019
- In October, Targovax was selected for oral presentation at
Society for Immunotherapy of Cancer (SITC) 2019 Annual Meeting. The
presentation was given by Dr. Alexander
Shoushtari, Principal Investigator of ONCOS-102 trial in
melanoma, Memorial Sloan Kettering Cancer Center, NYC
POST-PERIOD HIGHLIGHTS
- In January 2020, Targovax
announced it has entered into an option agreement with IOVaxis
Therapeutics for an TG mutant RAS vaccine license and clinical
development agreement in China
- In January 2020, Targovax
presented encouraging data in the mesothelioma study combining
ONCOS-102 and standard of care chemotherapy
- In January 2020, Targovax
successfully completed a private placement, raising gross proceeds
of approximately NOK 101 million
(USD 11.2 million)
- In March, Targovax announced completed enrollment in the
ONCOS-102 trial in anti-PD1 refractory melanoma
Øystein Soug, CEO commented: "2019 marked an
important milestone for Targovax as we started to see clinical
efficacy with ONCOS-102 in combination with checkpoint inhibitors
and chemotherapy. With the new data at hand, we have solidified our
position as a leader in the oncolytic virus field. While we
continue to treat patients and analyze data, we are preparing for
the next steps of the ONCOS program beyond the ongoing trials."
Presentation
The presentation will take place at 10:00
CET at:
Hotel Continental
Stortingsgaten 24/26
0117 Oslo
The presentation will also be webcast live and can be accessed
here.
Reporting material
Targvoax 4Q presentation
Targovax 4Q report
The quarterly report and presentation are also available at the
website www.targovax.com.
For further information, please contact:
Renate Birkeli, Investor
Relations
Phone: +47 922 61 624
Email: renate.birkeli@targovax.com
Media and IR enquires:
Andreas Tinglum - Corporate
Communications (Norway)
Phone: +47 9300 1773
Email: andreas.tinglum@corpcom.no
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/targovax/r/targovax-asa--fourth-quarter-2019-results,c3056757
The following files are available for download:
|
https://mb.cision.com/Public/17093/3056757/845f70d70d03c883.pdf
|
Targovax 4Q19
report
|
|
https://mb.cision.com/Public/17093/3056757/a1e484c8f18e9a85.pdf
|
Targovax 4Q19
presentation
|
View original
content:http://www.prnewswire.com/news-releases/targovax-asa-fourth-quarter-2019-results-301021327.html
SOURCE Targovax